Salivary Lysozyme and Glycosylated Lysozyme Levels of Type 2 Diabetic Patients in Comparison with Healthy Individuals

Document Type : Research Article

Authors

1 Department of Oral and Maxillofacial Medicine, School of Dentistry, Dental Research Center, Hamadan University of Medical Sciences, Hamadan, I.R. IRAN

2 Dental Research Center& Dental Implant Research Center, School of Dentistry, Hamadan University of Medical Sciences, Hamadan, I.R. IRAN

3 Department of Biostatistics, School of Health, Modeling of Noncommunicable Diseases Research Center, Health Sciences & Technology Research Institute, Hamadan University of Medical Sciences, Hamadan, I.R. IRAN

4 Department of Internal Medicine, School of Medicine, Shahid Beheshti Medical Educational Center, Hamadan University of Medical Sciences, Hamadan,, I.R. IRAN

5 Department of Oral and Maxillofacial Medicine, School of Dentistry, Hamadan University of Medical Sciences, Hamadan, I.R. IRAN

6 Department of Oral Medicine, Guilan University of Medical Sciences, Guilan, I.R. IRAN

Abstract

Diabetes is a complex metabolic disorder that can cause changes in the composition and function of saliva. Therefore, it seems that the study of saliva composition in patients with diabetes will help in its diagnosis, prognosis, and complications. The present study aimed to compare the saliva’s lysozyme and glycosylated lysozyme levels of patients with type 2 diabetes (T2D) in comparison with healthy individuals. Lysozyme and glycosylated lysozyme levels of salivary samples were measured using ELISA method. The results of this study showed that salivary lysozyme levels were lower in T2D patients. Meanwhile, the salivary glycosylated lysozyme levels were higher in T2D patients compared to control (p≤ 0.001). Salivary lysozyme levels in patients with long-term diabetes (more than three years) were significantly lower than those of T2D patients having the disease for three years. Also, salivary glycosylated lysozyme levels were significantly higher in patients with long-term diabetes (more than three years) than in patients with short-term diabetes (less than three years). In conclusion, the results of this study demonstrated that the salivary lysozyme level in patients with T2D was lower than in healthy individuals. Also, the salivary glycosylated lysozyme level of the T2D patients was higher than healthy individuals. Increased duration of T2D affliction also appears to be associated with increased salivary glycosylated lysozyme levels. Moreover, the increase of salivary glycosylated lysozyme was greater in patients with T2D than in healthy individuals. These findings indicate the important role of salivary glycosylated lysozymes in diagnosing and predicting the complications of diabetic patients.

Keywords

Main Subjects


[2] Alramadan M.J., Afroz A., Hussain S.M., Batais M.A., Almigbal T.H., Al-Humrani H.A., et al. Patient-Related Determinants of Glycaemic Control in People with Type 2 Diabetes in the Gulf Cooperation Council Countries: A Systematic Review, J. Diabetes Res., 9389265 (2018).
[3] Dodds M.W., Yeh C.K., Johnson D.A., Salivary Alterations in Type 2 (Non-Insulin-Dependent) Diabetes Mellitus and Hypertension, Community Dent. Oral Epidemiol., 28(5): 373-81 (2000).
[4] Azeez S.H., Jafar S.N., Aziziaram Z., Fang L., Mawlood A.H., Ercisli M.F., Insulin-Producing Cells from Bone Marrow Stem Cells Versus Injectable Insulin for the Treatment of Rats with Type I Diabetes, Cell Mol. Biomed Rep., 1(1): 42-51 (2021).
[5] Williams D.M, Jones H., Stephens J.W., Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations, Diabetes Metab. Syndr. Obes.: Targets Ther.,15: 281 (2022).
[6] Maruthur N.M., Tseng E., Hutfless S., Wilson L.M., Suarez-Cuervo C., Berger Z., et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-Analysis, Ann Intern. Med.,164(11): 740-51 (2016).
[10] Chandrasekar Lakshmi K., Sankarapandiyan S., Nagalingeswaran K., Kindo A., Ganesan N., Oral Candidal Carriage, Salivary Lysozyme Levels, and Their Relationship with CD 4 Count in HIV‐Infected Patients, J Investig Clin Dent., 7(1): 81-6 (2016).
[11] Mirmiranpour H., Khaghani S., Bathaie S.Z., Nakhjavani M., Kebriaeezadeh A., Ebadi M., et al., The Preventive Effect of L-Lysine on Lysozyme Glycation in Type 2 Diabetes, Acta Med. Iran, 54(1): 24-31 (2016).
[12] Qvarnstrom M., Janket S., Jones J.A., Nuutinen P., Baird A.E., Nunn M.E., et al., Salivary Lysozyme and Prevalent Hypertension, J. Dent. Res., 87(5): 480-4 (2008).
[13] Rathnayake N., Akerman S., Klinge B., Lundegren N., Jansson H., Tryselius Y., et al. Salivary Biomarkers for Detection of Systemic Diseases, PloS One., 8(4): e61356 (2013).
[14] Singh V.P., Bali A., Singh N., Jaggi A.S., Advanced Glycation End Products and Diabetic Complications, Korean J Physiol Pharmacol, 18(1): 1-14 (2014).
[15] Muratsu K., Morioka T., Levels of Salivary Lysozyme, Lactoperoxidase, and Lactoferrin in Diabetic Hamsters, Infect. Immun., 48(2): 389-94 (1985).
[16] Panchbhai A.S., Degwekar S.S., Bhowte R.R., Estimation of Salivary Glucose, Salivary Amylase, Salivary Total Protein and Salivary Flow rate in Diabetics in India, J. Oral Sci., 52(3): 359-68 (2010).
[17] Muraoka M.Y., Justino A.B., Caixeta D.C., Queiroz J.S., Sabino-Silva R., Salmen Espindola F., Fructose and Methylglyoxal-Induced Glycation Alters Structural and Functional Properties of Salivary Proteins, Albumin and Lysozyme, PloS One.,17(1): e0262369 (2022).
[18] Zalewska A., Knaś M., Kuźmiuk A., Waszkiewicz N., Niczyporuk M., Waszkiel D., et al. Salivary Innate Defense System in Type 1 Diabetes Mellitus in Children with Mixed and Permanent Dentition, Acta Odontol Scand., 71(6): 1493-500 (2013).
[20] Mandal A.K., Flaws in Diagnosis and Outcome of Diabetes, BAOJ Diabet., 2: 012 (2016).
[21] Kumar S., Padmashree S., Jayalekshmi R., Correlation of Salivary Glucose, Blood Glucose and Oral Candidal Carriage in the Saliva of Type 2 Diabetics: A Case-Control Study, Contemp. Clin. Dent., 5(3): 312-7 (2014).
[22] Bellagambi F., Lomonaco T., Salvo P., Vivaldi F.M., Hangouët M., Ghimenti S., et al. Saliva Sampling: Methods and Devices. An Overview, TrAC - Trends Anal. Chem.124: 115781.
[23] Abdolsamadi H., Mortazavi H., Ahmadi-motemayel F., Hasani M., Salivary Flow Rate and Alpha Amylase Levels in Type II Diabetic Patients vs. Healthy Subjuects, J. Dent. Sci., 9(2): 87-92 (2012).
[24] Ahmadi-Motamayel F., Fathi S., Goodarzi M.T., Borzouei S., Poorolajal J, Barakian Y., Comparison of Salivary Antioxidants and Oxidative Stress Status in Gestational Diabetes Mellitus and Healthy Pregnant Women. Endocr. Metab. Immune. Disord, Drug Targets., (2020).
[26] Fares S., Said M.S.M., Ibrahim W., Amin T.T., Saad N.E.S., Accuracy of Salivary Glucose Assessment in Diagnosis of Diabetes and Prediabetes, Diabetes Metab. Syndr.: Clin. Res. Rev., 13(2):1543-7 (2019).
[27] Tiongco R-E, Bituin A., Arceo E., Rivera N., Singian E., Salivary Glucose as a Non-Invasive Biomarker of Type 2 Diabetes Mellitus, Diabetes Metab. Syndr.: Clin. Res. Rev., 10 (2018).
[28] Tiongco R.E.G., Arceo E.S., Rivera N.S., Flake C.C.D., Policarpio A.R., Estimation of Salivary Glucose, Amylase, Calcium, and Phosphorus Among Non-Diabetics and Diabetics: Potential Identification of Non-Invasive Diagnostic Markers, Diabetes Metab. Syndr.: Clin. Res. Rev., 13(4): 2601-5 (2019).
[29] Belstrøm D., Holmstrup P., Bardow A., Kokaras A., Fiehn N-E., Paster B.J., Comparative Analysis of Bacterial Profiles in Unstimulated and Stimulated Saliva Samples, J. Oral Microbiol., 8(1): 30112 (2016).
[30] Li-Hui W., Chuan-Quan L., Long Y., Ru-Liu L., Long-Hui C., Wei-Wen C., Gender Differences in the Saliva of Young Healthy Subjects before and after Citric Acid Stimulation, Clinica Chimica Acta; International Journal of Clinical Chemistry., 460: 142-5 (2016).
[31] Mosca A.C., Stieger M., Neyraud E., Brignot H., van de Wiel A., Chen J., How are Macronutrient Intake, BMI, Ethnicity, Age, and Gender Related to the Composition of Unstimulated Saliva? A Case Study, J. Texture Stud., 50(1): 53-61 (2019).
[32]  Xu F., Laguna L., Sarkar A., Aging-Related Changes in Quantity and Quality of Saliva: Where do we Stand in our Understanding?, J. Texture Stud., 50(1): 27-35 (2019).
[33] Rathnayake N., Åkerman S., Klinge B., Lundegren N., Jansson H., Tryselius Y., et al., Salivary Biomarkers for Detection of Systemic Diseases, PloS one., 8(4): e61356 (2013).
[34] Reuterving C.O., Reuterving G., Hägg E., Ericson T., Salivary Flow Rate and Salivary Glucose Concentration in Patients with Diabetes Mellitus Influence of Severity of Diabetes, Diabetes Metab., 13(4): 457-62 (1987).
[35] Verma M., Paneri S., Badi P., Raman P.G., Effect of Increasing Duration of Diabetes Mellitus Type 2 on Glycated Hemoglobin and Insulin Sensitivity, Indian J. Clin. Biochem., 21(1): 142-6 (2006).
[36] Ben-Aryeh H., Serouya R., Kanter Y., Szargel R., Laufer D., Oral Health and Salivary Composition in Diabetic Patients, J. Diabetes Complicat. 7(1): 57-62 (1993).
[37] Carramolino-Cuéllar E., Lauritano D., Silvestre F-J., Carinci F., Lucchese A., Silvestre-Rangil J., Salivary Flow and Xerostomia in Patients with Type 2 Diabetes, J. Oral Pathol. Med., 47(5): 526-30 (2018).
[38] Nurdiana N., Mardia I., Relationship between Glycemic Control and Coated Tongue in Type 2 Diabetes Mellitus Patients with Xerostomia, Pesqui. Bras. Odontopediatxria Clin., 19: 1-8 (2019).
[40] Huang Y., Li Y., Chen Q., Chen H., Ma H., Su Z., et al. Low Serum Adiponectin Levels are Associated with Reduced Insulin Sensitivity and Lipid Disturbances in Short Children Born Small for Gestational Age, Clin. Endocrinol., 83(1): 78-84 (2015).
[41] InterAct C., Scott R.A., Langenberg C., Sharp S.J., Franks P.W., Rolandsson O., et al. The Link between Family History and Risk of Type 2 Diabetes is Not Explained by Anthropometric, Lifestyle or Genetic Risk Factors: The EPIC-InterAct Study, Diabetologia., 56(1): 60-9 (2013).